Bionano Genomics Inc Units Cons of 1 Sh + 1 Wt 20.08.23

Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.

Bionano Genomics

BNGO stock shot up massively in the past few months. Now isn't the time to invest as the company must first prove its technology sells.

Bionano Genomics Would Have Been a Great Find Months Ago

Nano Dimension

Let's take a look at two companies that Wood has her eye on and has recently added to Ark's large portfolio of funds.

2 Stocks that Ark Invest loves for 2021

BNGO stock is an investment in the future of gene discovery and therapy as Bionano pushes the boundaries of optical genome mapping tech. The post Leverage the Power of Genetics Tech With Bionano Genomics appeared first on InvestorPlace.

Leverage the Power of Genetics Tech With Bionano Genomics

Bionano Genomics (BNGO) stock is on the move Wednesday with heavy trading following an update from the Nasdaq about its listing status. The post Bionano Genomics News: Why BNGO Stock Is Rallying Today appeared first on InvestorPlace.

Bionano Genomics News: Why BNGO Stock Is Rallying Today

Bionano Genomics, Inc. (BNGO) CEO Dr. Erik Holmlin on Q3 2020 Results - Earnings Call Transcript

Bionano Genomics, Inc. (BNGO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Bionano Genomics, Inc. (BNGO) Upgraded to Buy: What Does It Mean for the Stock?

Bionano Genomics, Inc. (BNGO) CEO Erik Holmlin on Q2 2020 Results - Earnings Call Transcript

Bionano Genomics, Inc. operates in the genome analysis industry. The company sells its flagship product called Saphyr system, which helps accelerate the study of changes in chromosomes.

Bionano Genomics Has Upside Potential In The Stock Price

Bionano Genomics, Inc.'s (BNGO) CEO Dr.

Bionano Genomics, Inc. (BNGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

What Makes Bionano Genomics, Inc. (BNGO) a New Strong Buy Stock

Appointments add proven business leadership with strategic knowledge of commercialization of diagnostics to support Bionano’s mission of developing solutions in digital cytogenetics and genomics research Appointments add proven business leadership with strategic knowledge of commercialization of diagnostics to support Bionano’s mission of developing solutions in digital cytogenetics and genomics research

Bionano Genomics Adds Healthcare and Genomics Industry Experts with Experience in Commercialization and Reimbursement to Its Board of Directors

University of Iowa to use Bionano-based assay to replace most “gold standard” Southern blot tests for molecular diagnosis of FSHD University of Iowa to use Bionano-based assay to replace most “gold standard” Southern blot tests for molecular diagnosis of FSHD

Largest North American Site for FSHD Muscular Dystrophy Testing Adopts Bionano Genomics’ Saphyr for Majority of Clinical Tests 

SAN DIEGO, April  02, 2020  (GLOBE NEWSWIRE) -- BIONANO GENOMICS, INC. (NASDAQ: BNGO), a genome analysis company that provides tools and services based on its Saphyr® system to scientists and clinicians conducting genetic research and patient testing, today announced the pricing of an underwritten public offering of 54,546,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and common warrants to purchase up to an aggregate of 54,546,000 shares of common stock. Each share of common stock and, as applicable, each pre-funded warrant is being sold together with a common warrant to purchase one share of common stock at a combined effective price to the public of $0.33 per share and accompanying common warrant. For each pre-funded warrant Bionano sells, the number of shares of common stock Bionano is offering will be decreased on a one-for-one basis.

BIONANO GENOMICS ANNOUNCES PRICING OF $18 MILLION UNDERWRITTEN PUBLIC OFFERING

Bionano Genomics, Rescale, Amazon Web Services, and Genoox are donating consumables and compute resources to this effort based in Hannover, Germany Bionano Genomics, Rescale, Amazon Web Services, and Genoox are donating consumables and compute resources to this effort based in Hannover, Germany

Bionano Genomics to Support Largest Study to Date on COVID-19 Disease Susceptibility

Top researchers present their discoveries using Bionano’s genome imaging technology Top researchers present their discoveries using Bionano’s genome imaging technology

Bionano Genomics Data Drives Scientific Discoveries in Solid Tumors and Leukemias, To Be Presented at the 2020 AGBT Conference

A new generation of Bionano-based assays to be brought to the clinic by GeneDx A new generation of Bionano-based assays to be brought to the clinic by GeneDx

Bionano Genomics’ Saphyr® System is Adopted by GeneDx for the Clinical Detection of Genetic Variants in Muscular Dystrophies, Developmental and Reproductive Disorders

Bionano Genomics, Inc. (NASDAQ: BNGO) shares are trading higher after the company announced on Thursday that Novogene has adopted the Saphyr system for genome imaging and incorporated it into their expansive repertoire of genome analysis technology services.

News for Bionano Genomics Inc Units Cons of 1 Sh + 1 Wt 20.08.23 Stock (BNGOU)